乙酰胺,2-(3,4-二氢-3,3-二甲基-1(2H)-异喹啉亚基)-N-(2-甲基苯基)- | 74697-28-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 中文名称: 乙酰胺,2-(3,4-二氢-3,3-二甲基-1(2H)-异喹啉亚基)-N-(2-甲基苯基)-
• 中文别名: 乙基({8-氯-3-[2-(二乙基氨基)乙基]-4-甲基-2-氧代-2H-苯并吡喃-7-基}氧基)乙酸酯盐酸盐(1:1)；氯烯
• 英文名称: Cloricromen hydrochloride
• 英文别名: ethyl 2-[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxochromen-7-yl]oxyacetate;hydrochloride
• CAS: 74697-28-2
• 化学式: C20H27Cl2NO5
• 分子量: 432.3
• InChiKey: CCCZJRFQJNGCCU-UHFFFAOYSA-N

物化性质

• 熔点：
  221-222.3 °C
• 溶解度：
  DMSO：可溶，17mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  4.0
• 重原子数：
  28
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  65.1
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22

文献信息

• IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
  申请人：CAMP4 THERAPEUTICS CORPORATION

  公开号：US20210254056A1

  公开（公告）日：2021-08-19

  The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.
• US4296039A
  申请人：——

  公开号：US4296039A

  公开（公告）日：1981-10-20
• [EN] NEW PHARMACEUTICAL PREPARATIONS, CONTAINING 8-CHLORO-3(betaDIETHYLAMINOETHYL)-4-METHYL-7-ETHOXYCARBONYLMETHOXY COUMARIN AND THE SALTS THEREOF, IN THE TREATMENT OF PATHOLOGICAL CONDITIONS INVOLVING HIGH RELEASE OF NITRIC OXIDE<br/>[FR] NOUVELLES PREPARATIONS PHARMACEUTIQUES, CONTENANT DE LA 8-CHLORO-3-(BETA-DIETHYLAMINOETHYL)-4-METHYL-7-ETHOXYCARBONYLMETHOXYCOUMARINE ET SES SELS, UTILISEES DANS LE TRAITEMENT DES AFFECTIONS ENTRAINANT UNE FORTE LIBERATION D'OXYDE NITRIQUE
  申请人：FIDIA S.P.A.

  公开号：WO1995000142A1

  公开（公告）日：1995-01-05

  (EN) A pharmaceutical composition which comprises as an active ingredient, an effective amount of 8-chloro-3(beta-diethylaminoethyl)-4-methyl-7-ethoxycarbonylmethoxy coumarin or a pharmaceutically acceptable salt thereof, for the treatment of pathological conditions involving high release of nitric oxide (NO).(FR) Préparation pharmaceutique dont le composant actif est une quantité efficace de 8-chloro-3-(bêta-diéthylaminoéthyl)-4-méthyl-7-éthoxycarbonylméthyloxycoumarine ou un sel pharmaceutiquement acceptable de celle-ci, servant au traitement des maladies entraînant une forte libération d'oxyde nitrique (NO).
• [EN] IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS<br/>[FR] IDENTIFICATION ET MODULATION CIBLÉE DE RÉSEAUX DE SIGNALISATION GÉNIQUE
  申请人：CAMP4 THERAPEUTICS CORP

  公开号：WO2018204764A1

  公开（公告）日：2018-11-08

  The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.